Dr. Schué has over 15 years of experience in life science research. Prior to joining Cilcare, he managed R&D operations in a biotech company specialized in the development of therapeutic proteins to treat cystic fibrosis and chronic pancreatitis. He successfully brought drug candidates from preclinical to clinical phases and handled the preparation of regulatory documents to support Phase 2 CTA. Mathieu leads projects to define innovative development plan strategies of drug candidates specifically for ear disorders as well as identifying reference compounds in the various indications of hearing for Cilcare’s clients.